-
公开(公告)号：US12048718B2
公开(公告)日：2024-07-30
申请号：US16307854
申请日：2017-06-07
发明人： Armin Rehm , Uta Elisabeth Höpken , Julia Bluhm , Wolfgang Uckert , Elisa Kieback , Stephen Marino
CPC分类号： A61K35/17 , A61K47/65 , C07K14/70596 , C07K16/2878 , C12N15/62 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/622 , C07K2317/73 , C07K2319/03
摘要： The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.
-
公开(公告)号：US20240201207A1
公开(公告)日：2024-06-20
申请号：US18287532
申请日：2022-04-19
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2333/475 , G01N2333/912 , G01N2800/368 , G01N2800/50
摘要： The invention pertains to a method for the prediction of preeclampsia in a pregnant female human subject until the end of gestational week 16 of pregnancy based on metabolites from a blood sample obtained from said subject. According to the invention, the method comprises the following steps:
measuring the level of the following metabolites in the sample: 14,15-DHET, 13-HODE, 10,11-EDP, 21-HDHA, and 11,12-DHET, and
concluding based on the measured level whether the subject is likely to develop preeclampsia.-
公开(公告)号：US11981721B2
公开(公告)日：2024-05-14
申请号：US17193182
申请日：2021-03-05
发明人： Wolfgang Uckert , Mario Bunse , Julian Clauss , Zsuzsanna Izsvák
IPC分类号： C07H21/02 , A61P31/00 , A61P35/00 , C07H21/04 , C07K14/725 , C12N5/10 , C12N9/12 , C12N15/113 , C12N15/85 , C12N15/90
CPC分类号： C07K14/7051 , A61P31/00 , A61P35/00 , C12N5/10 , C12N9/1241 , C12N15/113 , C12N15/85 , C12N15/90 , C12Y207/07 , C12N2310/141 , C12N2800/22 , C12N2800/24 , C12N2800/90 , C12N2840/20
摘要： The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.
-
公开(公告)号：US20230025572A1
公开(公告)日：2023-01-26
申请号：US17933088
申请日：2022-09-17
IPC分类号： C07K14/725 , C07K16/28 , G01N33/574 , C07K14/705 , C07K16/30
摘要： The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new approaches for immune therapy, specifically adoptive T cell therapy, for treating cancer.
-
公开(公告)号：US11384071B2
公开(公告)日：2022-07-12
申请号：US16466907
申请日：2017-12-07
IPC分类号： C07D405/12 , A61K9/00 , A61K31/53 , C07D417/12 , A61P25/04
摘要： Chemical compounds that are useful as inhibitors of mechanotransduction in the treatment of pain and modulation of touch perception and topical administration of the compounds described herein in the treatment of pain and modulation of touch perception.
-
公开(公告)号：US20220002797A1
公开(公告)日：2022-01-06
申请号：US17281269
申请日：2019-08-13
IPC分类号： C12Q1/6869 , C12Q1/6806
摘要： The present disclosure provides a method for analyzing a polyribonucleotide, wherein the polyribonucleotide is an mRNA molecule with a poly(A) tail, said method comprising: (a) obtaining a labeled polyribonucleotide by GI tailing; followed by (b) providing a second molecule comprising a first primer recognition sequence followed by a sequence of C nucleotide residues linked to a sequence of T nucleotide residues; followed by (c) obtaining a complex of said labeled polyribonucleotide and said second molecule; followed by (d) obtaining an extended second molecule by (d1) extending the 3′ end of the second molecule by synthesizing a sequence that is complementary to the labeled polyribonucleotide; followed by (d2) extending the 3′ end of the second molecule by adding at least 1 to 5 C nucleotide residues, followed by a second primer recognition sequence; said method providing information on entire polyribonucleotides, in particular mRNA isoforms and their respective poly(A) tails.
-
公开(公告)号：US20210079108A1
公开(公告)日：2021-03-18
申请号：US17079075
申请日：2020-10-23
发明人： Felix Oden , Stephen Marino , Oliver Daumke
摘要： A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.
-
公开(公告)号：US10731163B2
公开(公告)日：2020-08-04
申请号：US15508424
申请日：2015-09-02
IPC分类号： C12N15/113 , C12Q1/6897
摘要： An antisense oligonucleotide comprising a sequence targeted to the 3′ untranslated region (3′ UTR) of the TNFAIP3 (A20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.
-
9.发明申请公开(公告)号：US20180051025A1
公开(公告)日：2018-02-22
申请号：US15552556
申请日：2016-02-24
发明人： Michael BADER , Edgar SPECKER , Susann MATTHES , Anja SCHÜTZ , Keven MALLOW , Maik GROHMANN , Marc NAZARÉ
IPC分类号： C07D473/06 , C07D519/00
CPC分类号： C07D473/06 , C07D487/04 , C07D519/00
摘要： The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
-
公开(公告)号：US09040238B2
公开(公告)日：2015-05-26
申请号：US13380147
申请日：2010-06-22
CPC分类号： C12Q1/6853 , C12Q1/6883 , C12Q2535/125 , C12Q2535/131
摘要： The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.
摘要翻译： 本发明涉及选自以下的多核苷酸：a）编码多肽RBM20的多核苷酸，其包含人多肽RBM20的P638L突变，或大鼠多肽RBM20的P641L突变，b）具有多核苷酸的反向互补序列的多核苷酸 a）和c）与上述a）或b）的多核苷酸具有至少50％同一性的多核苷酸。
-
-
-
-
-
-
-
-
-
搜索结果
72 条记录 (耗时 0.025 秒)
